Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Br J Nutr ; 116(11): 1869-1877, 2016 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-27974055

RESUMEN

Aberrant microbiota composition and function have been linked to several pathologies, including type 2 diabetes. In animal models, prebiotics induce favourable changes in the intestinal microbiota, intestinal permeability (IP) and endotoxaemia, which are linked to concurrent improvement in glucose tolerance. This is the first study to investigate the link between IP, glucose tolerance and intestinal bacteria in human type 2 diabetes. In all, twenty-nine men with well-controlled type 2 diabetes were randomised to a prebiotic (galacto-oligosaccharide mixture) or placebo (maltodextrin) supplement (5·5 g/d for 12 weeks). Intestinal microbial community structure, IP, endotoxaemia, inflammatory markers and glucose tolerance were assessed at baseline and post intervention. IP was estimated by the urinary recovery of oral 51Cr-EDTA and glucose tolerance by insulin-modified intravenous glucose tolerance test. Intestinal microbial community analysis was performed by high-throughput next-generation sequencing of 16S rRNA amplicons and quantitative PCR. Prebiotic fibre supplementation had no significant effects on clinical outcomes or bacterial abundances compared with placebo; however, changes in the bacterial family Veillonellaceae correlated inversely with changes in glucose response and IL-6 levels (r -0·90, P=0·042 for both) following prebiotic intake. The absence of significant changes to the microbial community structure at a prebiotic dosage/length of supplementation shown to be effective in healthy individuals is an important finding. We propose that concurrent metformin treatment and the high heterogeneity of human type 2 diabetes may have played a significant role. The current study does not provide evidence for the role of prebiotics in the treatment of type 2 diabetes.


Asunto(s)
Diabetes Mellitus Tipo 2/complicaciones , Disbiosis/dietoterapia , Microbioma Gastrointestinal/fisiología , Interacciones Huésped-Patógeno , Prebióticos , Trisacáridos/uso terapéutico , Adulto , Anciano , Biomarcadores/sangre , Estudios de Cohortes , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Diabetes Mellitus Tipo 2/microbiología , Método Doble Ciego , Disbiosis/complicaciones , Disbiosis/metabolismo , Disbiosis/microbiología , Endotoxemia/complicaciones , Endotoxemia/inmunología , Endotoxemia/microbiología , Endotoxemia/prevención & control , Estudios de Seguimiento , Microbioma Gastrointestinal/efectos de los fármacos , Interacciones Huésped-Patógeno/efectos de los fármacos , Humanos , Hipoglucemiantes/efectos adversos , Hipoglucemiantes/uso terapéutico , Mediadores de Inflamación/sangre , Resistencia a la Insulina , Mucosa Intestinal/efectos de los fármacos , Mucosa Intestinal/inmunología , Mucosa Intestinal/metabolismo , Mucosa Intestinal/microbiología , Londres , Masculino , Metformina/efectos adversos , Metformina/uso terapéutico , Persona de Mediana Edad , Veillonellaceae/efectos de los fármacos , Veillonellaceae/crecimiento & desarrollo , Veillonellaceae/inmunología , Veillonellaceae/fisiología
2.
Obesity (Silver Spring) ; 22(6): 1430-8, 2014 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-24715424

RESUMEN

OBJECTIVE: To investigate the effect of nutrient stimulation of gut hormones by oligofructose supplementation on appetite, energy intake (EI), body weight (BW) and adiposity in overweight and obese volunteers. METHODS: In a parallel, single-blind and placebo-controlled study, 22 healthy overweight and obese volunteers were randomly allocated to receive 30 g day(-1) oligofructose or cellulose for 6 weeks following a 2-week run-in. Subjective appetite and side effect scores, breath hydrogen, serum short chain fatty acids (SCFAs), plasma gut hormones, glucose and insulin concentrations, EI, BW and adiposity were quantified at baseline and post-supplementation. RESULTS: Oligofructose increased breath hydrogen (P < 0.0001), late acetate concentrations (P = 0.024), tended to increase total area under the curve (tAUC)420 mins peptide YY (PYY) (P = 0.056) and reduced tAUC450 mins hunger (P = 0.034) and motivation to eat (P = 0.013) when compared with cellulose. However, there was no significant difference between the groups in other parameters although within group analyses showed an increase in glucagon-like peptide 1 (GLP-1) (P = 0.006) in the cellulose group and a decrease in EI during ad libitum meal in both groups. CONCLUSIONS: Oligofructose increased plasma PYY concentrations and suppressed appetite, while cellulose increased GLP-1 concentrations. EI decreased in both groups. However, these positive effects did not translate into changes in BW or adiposity.


Asunto(s)
Adiposidad/efectos de los fármacos , Regulación del Apetito/efectos de los fármacos , Suplementos Dietéticos , Péptido 1 Similar al Glucagón/sangre , Oligosacáridos/administración & dosificación , Péptido YY/sangre , Adulto , Apetito/efectos de los fármacos , Área Bajo la Curva , Glucemia/metabolismo , Peso Corporal , Celulosa/administración & dosificación , Fibras de la Dieta/administración & dosificación , Ingestión de Energía/efectos de los fármacos , Ácidos Grasos/sangre , Femenino , Voluntarios Sanos , Humanos , Insulina/sangre , Masculino , Persona de Mediana Edad , Obesidad/metabolismo , Sobrepeso/metabolismo , Cooperación del Paciente , Método Simple Ciego , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA